|
Life Sciences Ontario Member's Directory
|
|
| Location: |
Markham, Ontario |
| Industry Sector: |
Public / Non-Profit Organizations / Medical Facilities |
| Website: |
www.techconnex.ca |
| Contact: |
John Cameron (Array)
1 905 4154558 |
| Description: |
TechConnex provides sector specific learning and networking opportunities to help the nearly 10,000 GTA technology companies. The company is a business development hub that presents opportunities to work with other members. |
|
|
|
| Location: |
Mississauga, Ontario |
| Industry Sector: |
Biotechnology - R&D Services |
| Website: |
www.therapurebio.com |
| Contact: |
Rajan Puri (info@therapurebio.com)
1 905 2866200 |
| Description: |
Therapure Biopharma Inc. is a biopharmaceutical company focused on manufacturing complex biologics for the customers and on developing, manufacturing and selling blood and plasma-related therapeutic products. |
|
| Location: |
Thunder Bay, Ontario |
| Industry Sector: |
Public / Non-Profit Organizations / Medical Facilities |
| Website: |
www.tbrri.com |
| Contact: |
Lisa Niccoli (Array)
1 807 6847223 |
| Description: |
TheThunder Bay Regional Health Research Institute (TBRHRI) is an independent, not-for-profit corporation facilitates clinical research particularly in the area of imaging and related fields strategic to regional health care needs. Current research areas include but are not limited to cancer, cardiac disease, stroke, orthopaedics, Indigenous health, and lung disease. |
|
| Location: |
Cincinnati, Ohio |
| Industry Sector: |
Public / Non-Profit Organizations / Medical Facilities |
| Website: |
www.tera.org |
| Contact: |
Patricia McGinnis (tera@tera.org)
1 513 5427475 |
| Description: |
Toxicology Excellence for Risk Assessment (TERA) is a non-profit and tax-exempt organization organized for scientific and educational purposes. The firm's mission is to support the protection of public health by developing, reviewing and communicating risk assessment values and analyses; improving risk methods through research; and, educating risk assessors, managers, and the public on risk assessment issues. |
|
| Location: |
Toronto, Ontario |
| Industry Sector: |
Biotechnology - Therapeutics and Diagnostics |
| Website: |
triphaseco.com |
| Contact: |
Grant Gibson (info@triphaseco.com)
1 647 2551459 |
| Description: |
Triphase Accelerator Corporation is a company which acquires promising cancer therapies and accelerates their development from pre-IND to clinical proof-of-concept. The company is actively working on the development of its proprietary drug products TRPH-222 and TRPH-395 as well as continuing to collaborate with Bristol-Myers Squibb on the development of marizomib. TRPH-222 is a novel, site-specific antibody-drug conjugate (ADC) targeting CD22, a B-cell-restricted sialo-glycoprotein that is an important modulator of B-cell signaling and survival, which is expressed on nearly all B-cell malignancies. TRPH-395 is a novel small molecule inhibitor that disrupts WDR5 protein-protein interactions. WDR5, a WD repeat family protein, has an established role in leukemia and lymphoma through its association with histone methyltransferase complexes. |
|
|
|
